Molecule intelOpportunity: StrongEssential

Neostigmine

17 brands · 13 companies · product forms

ATC: N07AA01, S01EB06 1 DRAP alert

Opportunity snapshot

Launch attractiveness
62
Market saturation
33
Price room
100
Regulatory risk
50
17
brands
13
companies
Rs 414.02
median price
6
price points
25.09x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 12%

Price room

Across observed sources and strengths
CheapestRs 82.07
MedianRs 414.02
Most expensiveRs 2,059.06
Spread25.09×
Sources: DRAP-official, Servaid

max/min price ratio 25.09x across 6 trusted points (Rs 82.07-2059.06). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 9 live products for Neostigmine — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2024-10-28
Voluntary Recall Alert: Drug Product; Neo-Pyrolate Injection (Batch # 105B24) Manufactured

Why this score

Launch attractiveness

40% supply-gap(45) + 25% price-variation(100) + 20% low-competition(67) + 15% supply-disruption(40), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

13 canonical companies and 17 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 25.09x across 6 trusted points (Rs 82.07-2059.06). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2024-10-28 incl. recall/safety.

Confidence

Full coverage.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.